161 results
Keyword epoetin Remove keyword
-
List item
Human medicines highlights: Issue 27 - April 2011
Last updated: 06/05/2011Epostim ( epoetin alfa ) Intended for the treatment …
-
List item
Human medicine European public assessment report (EPAR): Aranesp
darbepoetin alfa, Anemia, Cancer, Kidney Failure, Chronic
Date of authorisation: 08/06/2001, Revision: 42, Authorised, Last updated: 13/01/2020patients who were administered epoetin alfa (Leyland-Jones B, 2003 … Leyland-Jones B, 2003) or epoetin beta (Henke M et al, 2003 … with cancer treated with epoetins. Further to the recommendations … -
List item
Human medicine European public assessment report (EPAR): Alli (previously Orlistat GSK)
orlistat, Obesity
Date of authorisation: 22/07/2007, Revision: 17, Authorised, Last updated: 24/08/2020methoxy polyethylene glycol-epoetin beta), Pegasys (peginterferon … methoxy polyethylene glycol-epoetin beta, used for the treatment … -
List item
News: Are you an SME interested in funding of Adverse Drug Reaction research through the European Commission's 7th Framework Programme?
Last updated: 27/07/2010for drug safety research: Epoetins and tumour progression, shortened … pancreatitis/pancreatic cancer. • Epoetins: Risk of tumour growth progression … -
List item
Human medicine European public assessment report (EPAR): Xenical
orlistat, Obesity
Date of authorisation: 29/07/1998, Revision: 24, Authorised, Last updated: 07/05/2020methoxy polyethylene glycol-epoetin beta), Pegasys (peginterferon … methoxy polyethylene glycol-epoetin beta, used for the treatment … -
List item
Human medicine European public assessment report (EPAR): Rubraca
rucaparib camsylate, Ovarian Neoplasms
Date of authorisation: 23/05/2018,
, 
, Revision: 5, Authorised, Last updated: 14/01/2021
-
List item
Human medicine European public assessment report (EPAR): Jakavi
ruxolitinib (as phosphate), Myeloproliferative Disorders, Polycythemia Vera
Date of authorisation: 23/08/2012, Revision: 22, Authorised, Last updated: 04/01/2021 -
List item
Human medicine European public assessment report (EPAR): Pegasys
peginterferon alfa-2a, Hepatitis C, Chronic, Hepatitis B, Chronic
Date of authorisation: 20/06/2002, Revision: 41, Authorised, Last updated: 22/12/2020methoxy polyethylene glycol-epoetin beta), Pegasys (peginterferon … methoxy polyethylene glycol-epoetin beta, used for the treatment … -
List item
Human medicine European public assessment report (EPAR): Xeloda
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 02/02/2001,
, Revision: 25, Authorised, Last updated: 30/07/2020
methoxy polyethylene glycol-epoetin beta), Pegasys (peginterferon … methoxy polyethylene glycol-epoetin beta, used for the treatment … -
List item
Human medicine European public assessment report (EPAR): Elaprase
idursulfase, Mucopolysaccharidosis II
Date of authorisation: 08/01/2007,, 
, Revision: 20, Authorised, Last updated: 24/06/2020
-
List item
Human medicine European public assessment report (EPAR): Tamiflu
oseltamivir, Influenza, Human
Date of authorisation: 20/06/2002, Revision: 39, Authorised, Last updated: 22/09/2020methoxy polyethylene glycol-epoetin beta), Pegasys (peginterferon … methoxy polyethylene glycol-epoetin beta, used for the treatment … -
List item
Human medicine European public assessment report (EPAR): Nespo
darbepoetin alfa, Kidney Failure, Chronic, Anemia, Cancer
Date of authorisation: 08/06/2001, Revision: 19, Withdrawn, Last updated: 28/01/2009 -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 July 2012
CHMP, Last updated: 20/07/2012methoxy polyethylene glycol-epoetin beta, peginterferon alfa-2a … -
List item
Withdrawn application: Aranesp
darbepoetin alfa, date of withdrawal: 21/02/2018, Post-authorisation, Last updated: 24/04/2018 -
List item
Withdrawn application: Omontys
date of withdrawal: 28/06/2013, Initial authorisation, Last updated: 28/06/2013with another medicine called epoetin. The main measure of effectiveness … -
List item
Withdrawn application: Orathecin
date of withdrawal: 19/01/2006, Initial authorisation, Last updated: 23/01/2006 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)20-23 June 2011
CHMP, Last updated: 24/06/2011epoetin zeta), from Hospira UK Ltd … neuropathy. Retacrit (epoetin zeta), from Hospira UK Ltd … -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir / dasabuvir / sofosbuvir / ledipasvir / simeprevir / ombitasvir/paritaprevir / ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Roxadustat
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001557-PIP01-13-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 17/04/2019, Last updated: 31/01/2019, Compliance check: Xthe European Union, such as Epoetin alfa, that are known to work … -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 16/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 29/01/2021 -
List item
PRAC recommendations on safety signals
Last updated: 06/01/2020 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 29/01/2021 -
List item
Public data from Article 57 database (updated)
Last updated: 16/02/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020